PE20140035A1 - INJECTABLE COMPOSITION INCLUDING A NON-STEROID ANTI-INFLAMMATORY AND AN ANTIBIOTIC - Google Patents
INJECTABLE COMPOSITION INCLUDING A NON-STEROID ANTI-INFLAMMATORY AND AN ANTIBIOTICInfo
- Publication number
- PE20140035A1 PE20140035A1 PE2013001576A PE2013001576A PE20140035A1 PE 20140035 A1 PE20140035 A1 PE 20140035A1 PE 2013001576 A PE2013001576 A PE 2013001576A PE 2013001576 A PE2013001576 A PE 2013001576A PE 20140035 A1 PE20140035 A1 PE 20140035A1
- Authority
- PE
- Peru
- Prior art keywords
- antibiotic
- composition including
- injectable composition
- steroid anti
- inflammatory
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 239000003125 aqueous solvent Substances 0.000 abstract 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 3
- MFSJSVNVUDQHLV-QHUNOZLZSA-N (2S)-2-(3-benzoylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1.OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFSJSVNVUDQHLV-QHUNOZLZSA-N 0.000 abstract 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 abstract 1
- 229930194936 Tylosin Natural products 0.000 abstract 1
- 239000004182 Tylosin Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 abstract 1
- 229960000588 flunixin Drugs 0.000 abstract 1
- SZMNOLSLNRNAJC-UHFFFAOYSA-N formaldehyde;propane-1,2,3-triol Chemical group O=C.OCC(O)CO SZMNOLSLNRNAJC-UHFFFAOYSA-N 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960000991 ketoprofen Drugs 0.000 abstract 1
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
- 210000005075 mammary gland Anatomy 0.000 abstract 1
- 229960001929 meloxicam Drugs 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 abstract 1
- 229960004059 tylosin Drugs 0.000 abstract 1
- 235000019375 tylosin Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION INYECTABLE QUE COMPRENDE: A) UN FARMACO ANTIINFLAMATORIO NO ESTEROIDEO (AINE) TAL COMO FLUNIXINA, MELOXICAM, CARPROFENO O KETOPROFENO, EN UNA CANTIDAD DE 1 A 15% P/V; B) UN ANTIBIOTICO MACROLIDO TAL COMO TILOSINA Y UN ANTIBIOTICO BETALACTAMICO TAL COMO PENETAMATO, EN UNA CANTIDAD DE 10 A 35% P/V; C) DOS DISOLVENTES NO ACUOSOS QUE ACTUAN COMO UN AGENTE SOLUBILIZADOR Y UN VEHICULO, EN EL QUE EL PRIMER DISOLVENTE NO ACUOSO ES GLICERINA FORMALDEHIDO O N-METIL-2-PIRROLIDONA (NMP) Y EL SEGUNDO DISOLVENTE NO ACUOSO ES PROPILENGLICOL; Y D) UN ANTIOXIDANTE TAL COMO SULFOXILATO FORMALDEHIDO DE SODIO O TOLUENO HIDROXIBUTILADO (BHT) EN UNA CANTIDAD DE 0,01 A 0,3% P/V; EN DONDE LA PROPORCION ENTRE EL AINE Y ANTIBIOTICO ES 1:3 P/V. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE UNA INFECCION MICROBIANA EN LA GLANDULA MAMARIA DE UN ANIMALIT REFERS TO AN INJECTABLE COMPOSITION INCLUDING: A) A NON-STEROID ANTI-INFLAMMATORY DRUG (NSAID) SUCH AS FLUNIXIN, MELOXICAM, CARPROPHENE OR KETOPROPHEN, IN AN AMOUNT OF 1 TO 15% w / V; B) A MACROLIDE ANTIBIOTIC SUCH AS TYLOSIN AND A BETHALACTAMIC ANTIBIOTIC SUCH AS PENETAMATE, IN A QUANTITY OF 10 TO 35% P / V; C) TWO NON-AQUEOUS SOLVENTS THAT ACT AS A SOLUBILIZING AGENT AND A VEHICLE, IN WHICH THE FIRST NON-AQUEOUS SOLVENT IS GLYCERIN FORMALDEHYDE OR N-METHYL-2-PYRROLIDONE (NMP) AND THE SECOND NON-AQUEOUS SOLVENT IS PROPYLENE GLYCOL; AND D) AN ANTIOXIDANT SUCH AS SODIUM FORMALDEHYDE SULFOXYLATE OR HYDROXIBUTYLED TOLUENE (BHT) IN AN AMOUNT OF 0.01 TO 0.3% W / V; WHERE THE RATIO BETWEEN THE NSAID AND ANTIBIOTIC IS 1: 3 P / V. SUCH COMPOSITION IS USEFUL IN THE TREATMENT OF A MICROBIAL INFECTION IN THE MAMMARY GLAND OF AN ANIMAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ588686A NZ588686A (en) | 2011-01-20 | 2011-01-20 | Injectable composition comprising an NSAID and an antibiotic in a non-aqueous solvent for treating a microbial infection in a mammary gland |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140035A1 true PE20140035A1 (en) | 2014-02-16 |
Family
ID=46515931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001576A PE20140035A1 (en) | 2011-01-20 | 2012-01-20 | INJECTABLE COMPOSITION INCLUDING A NON-STEROID ANTI-INFLAMMATORY AND AN ANTIBIOTIC |
Country Status (15)
| Country | Link |
|---|---|
| KR (1) | KR101905173B1 (en) |
| CN (1) | CN103327984B (en) |
| AU (1) | AU2012207698A1 (en) |
| BR (1) | BR112013018557B1 (en) |
| CL (1) | CL2013002086A1 (en) |
| CO (1) | CO6801732A2 (en) |
| CR (1) | CR20130401A (en) |
| GT (1) | GT201300182A (en) |
| IL (1) | IL227540A (en) |
| MX (1) | MX353876B (en) |
| NI (1) | NI201300063A (en) |
| NZ (1) | NZ588686A (en) |
| PE (1) | PE20140035A1 (en) |
| WO (1) | WO2012099479A1 (en) |
| ZA (1) | ZA201305780B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2995297A1 (en) * | 2014-09-09 | 2016-03-16 | Ceva Sante Animale | Parenteral compositions and uses thereof |
| AR102172A1 (en) | 2015-10-05 | 2017-02-08 | Química Luar S R L | A BACTERICIDE AND VIRUCIDE PHARMACEUTICAL COMPOSITION |
| CN105663037A (en) * | 2016-01-27 | 2016-06-15 | 成都乾坤动物药业有限公司 | Amoxicillin solution as well as preparation method and application thereof |
| CN112472667B (en) * | 2019-08-23 | 2022-11-15 | 北京欧博方医药科技有限公司 | Retxib long-acting injection and preparation method and application thereof |
| CN111035614B (en) * | 2019-12-20 | 2024-02-02 | 北京喜禽药业有限公司 | High-content terramycin injection and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6787568B1 (en) * | 2000-11-27 | 2004-09-07 | Phoenix Scientific, Inc. | Antibiotic/analgesic formulation and a method of making this formulation |
| CN1297319C (en) * | 2003-09-22 | 2007-01-31 | 王玉万 | Preparing pharmaceutics of medication containing antimicrobials by using silicone oil as medium |
| EP1677781A4 (en) | 2003-10-29 | 2008-11-19 | Idexx Lab Inc | Salts of pharmacologically active compounds |
| DE102004025324A1 (en) * | 2004-05-19 | 2005-12-08 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation for veterinary medicine, process for their preparation and their use |
-
2011
- 2011-01-20 NZ NZ588686A patent/NZ588686A/en unknown
-
2012
- 2012-01-20 CN CN201280005989.4A patent/CN103327984B/en active Active
- 2012-01-20 MX MX2013008407A patent/MX353876B/en active IP Right Grant
- 2012-01-20 AU AU2012207698A patent/AU2012207698A1/en not_active Abandoned
- 2012-01-20 WO PCT/NZ2012/000003 patent/WO2012099479A1/en active Application Filing
- 2012-01-20 KR KR1020137021988A patent/KR101905173B1/en active IP Right Grant
- 2012-01-20 PE PE2013001576A patent/PE20140035A1/en not_active Application Discontinuation
- 2012-01-20 BR BR112013018557-0A patent/BR112013018557B1/en active IP Right Grant
-
2013
- 2013-07-17 GT GT201300182A patent/GT201300182A/en unknown
- 2013-07-17 NI NI201300063A patent/NI201300063A/en unknown
- 2013-07-18 IL IL227540A patent/IL227540A/en not_active IP Right Cessation
- 2013-07-19 CL CL2013002086A patent/CL2013002086A1/en unknown
- 2013-07-31 ZA ZA2013/05780A patent/ZA201305780B/en unknown
- 2013-08-05 CO CO13186092A patent/CO6801732A2/en unknown
- 2013-08-19 CR CR20130401A patent/CR20130401A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013008407A (en) | 2013-09-26 |
| CN103327984B (en) | 2016-08-17 |
| AU2012207698A1 (en) | 2013-04-18 |
| ZA201305780B (en) | 2014-04-30 |
| CN103327984A (en) | 2013-09-25 |
| NZ588686A (en) | 2013-07-26 |
| GT201300182A (en) | 2014-07-28 |
| KR101905173B1 (en) | 2018-11-28 |
| BR112013018557A2 (en) | 2016-11-22 |
| IL227540A (en) | 2017-12-31 |
| CL2013002086A1 (en) | 2014-07-25 |
| IL227540A0 (en) | 2013-09-30 |
| CR20130401A (en) | 2014-02-04 |
| CO6801732A2 (en) | 2013-11-29 |
| KR20140012646A (en) | 2014-02-03 |
| WO2012099479A1 (en) | 2012-07-26 |
| NI201300063A (en) | 2014-05-23 |
| MX353876B (en) | 2018-02-01 |
| BR112013018557B1 (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7240372A2 (en) | Topical non-aqueous pharmaceutical formulations | |
| PE20140035A1 (en) | INJECTABLE COMPOSITION INCLUDING A NON-STEROID ANTI-INFLAMMATORY AND AN ANTIBIOTIC | |
| TR201902125T4 (en) | PARASITIDAL ORAL VETERINARY COMPOSITIONS CONTAINING SYSTEMICALLY ACTIVE AGENTS, THEIR METHODS AND USES | |
| SV2013004451A (en) | COMPOUNDS AND ITS USE | |
| ES2554245T3 (en) | Injectable parasiticidal formulations of levamisole and macrocyclic lactones | |
| CY1116111T1 (en) | LOCAL COMPOSITION FOR RADICAL CARE TREATMENT | |
| PE20190210A1 (en) | CARRIMYCIN APPLICATIONS IN INFECTION WITH RESISTANT MYCOBACTERIUM TUBERCULOSIS | |
| SV2011003907A (en) | ANTIMICROBIAL COMPOSITIONS | |
| PH12014502345B1 (en) | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | |
| BR122020011180B8 (en) | injectable formulations of tetracycline compounds | |
| AR052882A1 (en) | ANTIHELMINTIC COMPOSITION | |
| CL2008001477A1 (en) | Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain | |
| AR064152A1 (en) | ANTIBACTERIAL QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PREPARATION METHOD. | |
| PE20151726A1 (en) | STABLE VETERINARY FORMULATIONS OF COMBINATION OF MACROCYCLIC LACTONES AND IMIDAZOTHIAZOLES | |
| BR112019004923A2 (en) | sustained release buprenorphine formulations | |
| PE20110370A1 (en) | NIFURTIMOX FOR THE TREATMENT OF DISEASES CAUSED BY TRICHOMONADIDE | |
| BR112017028185A2 (en) | solid pharmaceutical compositions for treating hcv | |
| BR112018000982A2 (en) | solid pharmaceutical compositions for treating hcv | |
| WO2020053658A3 (en) | Non-aqueous chemotherapeutic solutions for oral dosage | |
| AR118214A1 (en) | NON-STEROID ANTI-INFLAMMATORY LYOPHILIZED PHARMACEUTICAL COMPOSITION | |
| CL2013000210A1 (en) | Thiophene 2,3,5 trisubstituted derivatives; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of a disorder or disease in a subject caused or associated with a HCV infection, such as liver cirrhosis, hepatocellular carcinoma, among others. | |
| UA130311U (en) | COMPOSITION WITH ANTIBERCULOSIS ACTION | |
| UA130656U (en) | COMPOSITION WITH ANTIBERCULOSIS ACTION | |
| AR100815A1 (en) | TRANSDERMAL PARASITICID FORMULATIONS, METHOD, USE | |
| UY28403A1 (en) | INJECTABLE PHARMACEUTICAL COMPOSITION OF TRICLABENDAZOL SULFOXIDE FOR THE TREATMENT AND / OR PREVENTION OF PHASCIOLASIS IN ANIMALS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |